Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Doxorubicin (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 29 Dec 2016 Status changed from recruiting to completed.
- 01 Oct 2015 New trial record
- 29 Sep 2015 According to an Eisai media release, additional approval has been received for the vascular embolization device DC Bead to be used for the treatment of hypervascular tumors and arteriovenous malformations in Japan.